The antibacterial activities of aditoprim and its efficacy in the treatment of swine streptococcosis.

Aditoprim (ADP) has potential use as an antimicrobial agent in animals. However, its pharmacodynamic properties have not been systematically studied yet. In this study, the in vitro antibacterial activities of ADP and its main metabolites were assayed, and the in vivo antibacterial efficacy of ADP for the treatment of swine streptococcosis was evaluated. It was shown that Salmonella and Streptococcus from swine, Escherichia coli and Salmonella from chickens, E. coli, Streptococcus, Mannheimia, Pasteurella from calves, Streptococcus and Mannheimia from sheep, and E. coli, Flavobacterium columnare, Acinetobacter baumannii and Yersinia ruckeri from fishes were highly susceptible to ADP. Haemophilus parasuis from swine, Staphylococcus aureus, Aeromonas punctate, Mycobacterium tuberculosis, Streptococcus agalactiae from fishes, and Klebsiella from calves and sheep showed moderate susceptibility to ADP, whereas E. coli, Actinobacillus pleuropneumonia, Pasteurella, S. aureus, Clostridium perfringens from swine, S. aureus, C. perfringens from chickens, and S. aureus from calves were resistant to ADP. The main metabolites of ADP showed equal activity to that of their parent compound, and the prevention and therapeutic dosages of ADP recommended for swine streptococcosis were 10 and 20~40 mg/kg b.w., respectively. This study firstly showed that ADP had strong antibacterial activity and had potential to be used as a single drug in the treatment of bacterial infectious diseases.

Aditoprim (ADP, 2,4-diamino-5-(4-[dimethylamino]-3,5-dimethoxybenzyl)pyrimidine), is a dihydrofolate reductase inhibitor which inhibits the transformation of dihydrofolic acid to tetrahydrofolic acid1. The chemical structure of ADP is similar to that of another 2,4-diaminopyrimidine, trimethoprim (TMP), which demonstrates inhibitory activity for most gram-positive aerobic cocci and Gram-negative aerobic bacilli, especially Staphylococcus aureus, Staphylococcus epidermidis, Group A beta-hemolytic streptococci, Streptococcus agalactiae, Streptococcus viridans, Streptococcus pneumoniae, Streptococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Enterobacter sp., Salmonella sp., Shigella sp., and Hemophilus infIuenzae234.

However, there are less studies on the pharmacodynamics of ADP at present. Early studies have demonstrated that ADP is a broad-spectrum drug, exhibiting antibacterial activity against many pathogens from food-producing animals, such as Haemophilus, Enterobacteriaceae, Aeromonas, Vibrio, Staphylococci, Streptococci, Acinetobacter and Alcaligenes (MICs ≤ 8 μg/mL, determined by using Diagnostic Sensitivity Test Agar)1. It is more active than sulfamethazine, sulfamethazine-TMP combination and tetracycline1. Another study using tube dilution method showed that the MICs of ADP were ranged from 5 to 20 μg/mL and the MBCs were ranged from 320 to 1280 μg/mL to E. coli, Salmonella cholerasuis, Steptococcus, S. aureus, and Pasteurella multocida (Li Shengbin, unpublished data). Since the methods used for MIC determination were not unified from different literatures, it is difficult to compare the results horizontally. Moreover, the kinds and numbers of bacteria were limited. Therefore, systematic research on the pharmacodynamics of ADP is urgently needed.

ADP has excellent pharmacokinetic characteristics. Previous studies have shown that ADP has longer elimination half lives (3.3~14.8 h) and higher distribution volumes (4.6~10.4 L/kg) than those of TMP in pig, calf, monkey, sheep and some other animal species567891011121314151617, and a similar pattern is observed for ADP where the distribution volume is about four times higher than that of TMP. For the poor pharmacokinetics18 and the development of antibacterial resistance192021, TMP is often used in combination with sulfonamides as antibacterial synergist for the treatment and prevention of bacterial infections in veterinary and human medicine22. In addition, the general toxicity, the mutagenicity, the reproductive toxicity and the teratogenicity studies of ADP have demonstrated that it shows low toxicities2324. These advantages make ADP a promising antibacterial agent in veterinary medicine.

ADP can be metabolized into 11, 9, 2 and 2 metabolites in swine, broilers, carp and rats, respectively, and N-monodesmethyl-ADP (A1) and N-didesmethyl-ADP (A2) are the main metabolites in their edible tissues25. In sheep, A1 and A2 also appear to be equally important metabolites26. Whether A1 or A2 has antibacterial activities, which is important for formulating the clinical dosage regimen, has not been studied.

Based on the related guidelines and standards of Clinical and Laboratory Standards Institute (CLSI), we determined the in vitro antibacterial activities of ADP, A1 and A2, and established the antimicrobial spectrum of ADP comprehensively and systematically in pathogenic bacteria from swine, chickens, fishes, calves and sheep in the present study. Phase II clinical trial was also carried out to evaluate the efficacy of ADP in the treatment of swine streptococcicosis. The deep knowledge about the pharmacodynamics of ADP will lay a solid foundation for the application of ADP as a new veterinary drug.

Results

The in vitro antibacterial activities of ADP and its metabolites

As shown in Table 1, 2 and 3, ADP has the same antibacterial spectrum as TMP. Salmonella and Streptococcus from swine, E. coli and Salmonella from chickens, E. coli, Streptococcus, Mannheimia, and Pasteurella from calves, Streptococcus and Mannheimia from sheep, and E. coli, Flavobacterium columnare, A. baumannii and Y. ruckeri from fishes were highly susceptible to ADP (MIC or MIC50 ≤ 4 μg/mL). H. parasuis from swine, S. aureus, Aeromonas punctate, Mycobacterium tuberculosis, and S. agalactiae from fishes, and Klebsiella from calves and sheep showed moderate susceptibility (MIC or MIC50 = 8~16 μg/mL), whereas E. coli, A. pleuropneumonia, Pasteurella, S. aureus, and C. perfringens from swine, S. aureus and C. perfringens from chickens, and S. aureus from calves were resistant to ADP (MIC or MIC50 ≥ 32 μg/mL). The values of MBC/MIC were from 1 to 4 for ADP against sensitive bacteria, which indicated that ADP had a good bactericidal activity.

Table 1

The MIC50, MBC50, MIC90 and MBC90 of ADP and TMP against common pathogenic bacteria isolated from swine, chickens and calves.

Origin	Strains (amount)	MIC50 (μg/mL)		MBC50 (μg/mL)		MBC50/MIC50		MIC90 (μg/mL)		MBC90 (μg/mL)		MBC90/MIC90
		ADP	TMP	ADP	TMP	ADP	TMP	ADP	TMP	ADP	TMP	ADP	TMP
Swine	E. coli (53)	64	64	128	128	2	2	>128	>128	>128	>128	—	—
	Salmonella (43)	2	2	8	8	4	4	64	64	128	128	2	2
	Streptococcus (44)	2	2	4	2	2	1	32	32	64	128	2	4
	A. pleuropneumonia (12)	128	>128	>128	>128	—	—	128	>128	>128	>128	—	—
	H. parasuis (31)	16	8	32	8	2	1	32	64	64	128	2	2
	Pasteurella (9)	64	64	128	128	2	2	64	>128	128	>128	2	—
Chicken	E. coli (33)	1	0.5	4	2	4	4	>128	128	>128	>128	—	—
	Salmonella (43)	1	1	2	4	2	4	8	8	16	16	2	2
Calves	E. coli (20)	4	2	16	8	4	4	16	16	128	128	8	8
	S. aureus (16)	128	128	>128	>128	—	—	>128	>128	>128	>128	—	—

Table 2

The MICs and MBCs of ADP and TMP against common pathogenic bacteria isolated from swine, chickens, calves and sheep.

Origin	Strains	Number	ADP		TMP
			MIC (μg/mL)	MBC (μg/mL)	MIC (μg/mL)	MBC (μg/mL)
Swine	S. aureus	207	32	128	16	32
	S. aureus	126b	32	128	16	64
	S. aureus	1256	64	128	128	>128
	S. aureus	586	64	>128	>128	>128
	C. perfringens	46P	>128	>128	64	>128
	C. perfringens	CVCC1160	>128	>128	>128	>128
	C. perfringens	45P	>128	>128	64	>128
	C. perfringens	55	>128	>128	>128	>128
	C. perfringens	F12P	>128	>128	64	>128
Chickens	S. aureus	107	64	>128	32	64
	S. aureus	12	>128	>128	64	>128
	C. perfringens	CVCC2030	>128	>128	>128	>128
	C. perfringens	12	>128	>128	>128	>128
Calves	Streptococcus	444	4	8	4	8
	Streptococcus	689	2	2	2	4
	Pasteurella	Hunag 4.26	2	2	2	4
	Pasteurella	Huang A	32	64	32	64
	Pasteurella	Stander B	32	128	32	128
	Pasteurella	16	4	8	4	8
	Klebsiella	145	8	32	8	32
	Klebsiella	350	4	8	4	16
	Klebsiella	340	16	64	16	64
Sheep	Mannheimia	MCMH	0.5	2	0.25	1
	Mannheimia	MH0529	0.5	2	0.25	1
	Pasteurella	1064	1	2	1	4
	Pasteurella	Hong 4.26	4	8	4	8
	Klebsiella	292	8	32	8	32
	Klebsiella	284	8	32	8	32
	Klebsiella	294	8	32	8	32

Table 3

The MICs and MBCs of ADP and TMP against common pathogenic bacteria isolated from fishes.

Strains	Number	ADP		TMP
		MIC (μg/mL)	MBC (μg/mL)	MIC (μg/mL)	MBC (μg/mL)
Y. ruckeri	SC90-2-4	0.5	1	4	4
E. coli	Se-1	0.5	1	1	2
Aeromonas punctata	58-20-9	8	16	>128	>128
Aeromonas hydrophils	Ah563	32	128	128	>128
Aeromonas hydrophils	Ah561	128	128	>128	>128
Aeromonas hydrophils	Ah78	128	128	>128	>128
Aeromonas hydrophils	SX91-4-1	128	128	>128	>128
Aeromonas caviae	DMA1-A	128	128	>128	>128
Aeromonas sobria	CR79-1-1	128	128	>128	>128
Aeromonas veronii	ATCC9071	128	128	>128	>128
Aeromonas jandaei	F30-3	128	128	>128	>128
Pseudomonas fluorescent	W81-11	128	128	>128	>128
Pseudomonas fluorescent	56-12-10	128	128	>128	>128
Flavobacterium columnare	G4	2	4	2	4
Edwardsiella ictaluri	HSN-1	128	128	>128	>128
Streptococcus agalactiae	XQ-1	8	16	8	16
S. aureus	Fs1	32	64	32	64
S. aureus	Fs2	8	16	16	32
M. tuberculosis	Asc-1.2 II	4	8	8	8
M. tuberculosis	Asc-1.3 II	8	16	8	32
M. tuberculosis	Asc-1.3V	8	16	8	16
M. tuberculosis	Cst-t-10	16	64	32	64
A. baumanii	Ab1	128	128	>128	>128

ADP and TMP had equal in vitro activity against E. coli, Salmonella and Streptococcus from swine, and F. columnare from fishes. Salmonella from chicken, E. coli, Streptococcus, Mannheimia, and Pasteurella from calves, Streptococcus and Mannheimia from sheep, and E. coli, A. punctate, A. baumannii, M. tuberculosis, S. agalactiae, S. aureus and Y. ruckeri from fishes were more susceptible to ADP than to TMP, whereas the MICs and MBCs of ADP against E. coli from calves and chicken were slightly higher than those of TMP.

For those facultative anaerobes, the MIC and MBC of ADP for a single strain or the MIC50, MBC50, MIC90 and MBC90 for more strains were equal or differed by only one gradient (2-fold) in the anaerobic and aerobic conditions, indicating that ADP also showed strong antibacterial and bactericidal activity against facultative anaerobes in anaerobic conditions.

As shown in Table 4, the MIC50, MBC50, MIC90 and MBC90 of A1 and A2 against Streptococcus from swine and Salmonella from chickens were equal to those of the parent drug ADP, from which we can draw a conclusion that the in vitro antibacterial activities of ADP and its main metabolites, A1 and A2, are equally potent.

Table 4

The MIC50, MBC50, MIC90 and MBC90 of ADP and its metabolites against Streptococcus from swine and Salmonella from chickens.

	ADP	A1	A2
Streptococcus from swine
MIC50 (μg/mL)	2	2	2
MBC50 (μg/mL)	4	4	4
MBC50/MIC50	2	2	2
MIC90 (μg/mL)	32	32	32
MBC90 (μg/mL)	64	64	64
MBC90/MIC90	2	2	2
Salmonella from chickens
MIC50 (μg/mL)	1	1	1
MBC50 (μg/mL)	2	2	2
MBC50/MIC50	2	2	2
MIC90 (μg/mL)	8	8	8
MBC90 (μg/mL)	16	16	16
MBC90/MIC90	2	2	2

Efficacy of ADP in the treatment of swine streptococcicosis

No clinical signs of streptococcicosis were seen in any of the swine during acclimation period prior to the infection challenge. During the treatment period, the mean rectal temperatures of pigs in the high-dose treatment group, the middle-dose treatment group and the positive group returned to normal level on the second day, and the mean temperature in the low-dose treatment group was back to normal level on the third day, whereas the temperature in the negative control group returned to normal on the ninth day (Fig. 1).

Figure 1

Changes in the mean rectal temperatures in each of the six groups of swine.

The infected swine were treated once daily with indicated doses of ADP or Compound Sulfadiazine Sodium (Positive control) from Day 0 to Day 5. The average rectal temperatures of the healthy (Blank) and treated or untreated (Negative control) infected swine were observed and recorded from Day 0 to Day 20.

All swine in the infected groups showed lethargy and loss of appetite before their first dose, whereas about 30% and 60% of the swine developed limping and respiratory symptoms, respectively. Three swine in the negative control group developed symptoms of sliding on Day 2 and Day 3 and then died on the next day. Autopsy results showed a large amount of severe fibrino exudation on the serosa of lung and kidney, bleeding point on the liver and spleen and enlargement of mesenteric lymph nodes (Supplementary Fig. S1). The histopathological study revealed a brain neuron atrophy, splenic nodule reduction, polycythemia, and existence of inflammatory cells and a small number of erythropoiesis in lung. Modified particles of hepatocyte and glomeruli swollen were also found as shown in Supplementary Fig. S2.

Swabs from the center of the lung lesions from the dead swine appeared alpha-hemolysis on 5% sheep blood agar plates (Supplementary Fig. S3A). Selected individual bacterial colony was confirmed by PCR, which showed 498 bp and 566 bp DNA bands corresponding to the sizes of CPS-2J and GDH genes which are specific for S. suis serotype 2 and Streptococcus, respectively (Supplementary Fig. S3B). The above results indicated that the deaths of swine were caused by S. suis infection.

The symptoms of most of the swine in the treatment groups were back to normal after dosing of ADP on Day 2 of the high-dose treatment group and the middle-dose treatment group and on Day 3 of the Compound Sulfadiazine Sodium positive-control group and the low-dose treatment group. Three swine in the low-dose treatment group and one in the middle-dose treatment group usually showed moderate or mild cough and somnolence. Coughing was noted in two swine in the low-dose treatment and one in the middle-dose treatment group. The mean “clinical score” of per swine were showed in Fig. 2.

Figure 2

Changes in the mean clinical scores in each of the six groups of swine.

The infected swine were treated once daily with indicated doses of ADP or Compound Sulfadiazine Sodium (Positive control) from Day 0 to Day 5. The average clinical scores of the healthy (Blank) and treated- or untreated- (Negative control) infected swine were observed and recorded from Day 0 to Day 20.

In order to evaluate the therapeutic effect of ADP on swine streptococcosis, a comprehensive analysis was done about coughing, mental state, body temperature and other symptoms of each group. As shown in Table 5, there were no deaths in the three ADP-treated groups, whereas the survival rate of the negative control group was 70%. The high-dose group of ADP showed 100% efficiency rate and cure rate, while both of the effective rate and the cure rate of the middle-dose group and the positive drug control group were 90%. The cure rate and the effective rate of the low-dose group were 80% and 70%, respectively (Table 5).

Table 5

The efficacy of ADP in the treatment of swine streptococcicosis.

Group (n = 10)	Survival rate (%)	Mortality rate (%)	Effective rate (%)	Cure rate (%)
Blank	100	0	—	—
Negative control	70	30	—	—
Positive control	100	0	90	90
Low-dose treatment group (10 mg/kg b.w.)	100	0	80	70
Middle-dose treatment group(20 mg/kg b.w.)	100	0	90	90
High-dose treatment group (40 mg/kg b.w.)	100	0	100	100

The body weights of the swine in each group were tested and compared before and after the experiment (Table 6). The relative weight gain rate (RAW) of Compound Sulfadiazine Sodium control group (93.0%) was between those of the high-dose treatment group (96.5%) and the middle-dose treatment group (91%), without significant difference between each other (P > 0.05). In the low-dose treatment group, the RAW was 74.7%, which is significantly different when compared with those of the high-dose group and the middle-dose group (P < 0.05). Swine in the negative control group gained an average weight of only 1.77 kg with RAW of 34.5%, showing a significant difference with those of the high-dose, the middle-dose and the low-dose groups (P < 0.05).

Table 6

Changes of the mean group weight.

Group (n = 10)	Initial weight (kg)	Final weight (kg)	Net gain (kg)	RWG (%)
Blank	12.29 ± 0.62	17.42 ± 1.11	5.13	100.0a
Negative control	12.59 ± 0.64	14.36 ± 0.69	1.77	34.5c
Positive control	12.40 ± 0.60	17.17 ± 0.84	4.77	93.0a
Low-dose treatment group (10 mg/kg b.w.)	12.51 ± 0.69	16.34 ± 0.93	3.83	74.7b
Middle-dose treatment group (20 mg/kg b.w.)	12.47 ± 0.51	17.14 ± 0.70	4.67	91.0a
High-dose treatment group (40 mg/kg b.w.)	12.56 ± 0.76	17.51 ± 0.54	4.95	96.5a

RWG: relative weight gain rate. a,b,cStatistically significant differences between groups indicated by different letters (P < 0.05).

Discussion

As a newly developing veterinary drug, ADP has turned out to be low toxic and not mutagenic2324. It exhibits longer half-life in animals than the representative drug of 2, 4-diaminopyrimidines, TMP, probably due to the dimethylamino group, which is vital for lengthened elimination rate in this compound27. In this study, the antimicrobial activities of ADP against zoonotic pathogens were investigated systematically and were compared with TMP. Results showed that ADP had a similar degree of in vitro antibacterial activities as those of TMP. Many gram-positive and gram-negative bacteria are highly susceptible or susceptible to ADP, especially Salmonella and Streptococcus, while H. parasuis and Klebsiella were moderately susceptible to ADP. Previous study showed that Pseudomonas aeruginosa, Campylobacter spp, Actinomyces and Clostridium spp. presented natural resistance to TMP and ADP1, which was validated in this study. In contrast, S. aureus are resistant to ADP and TMP in our study, which may be due to the single mutation (Phe98 to Tyr98) in the dihydrofolate reductase of S. aureus282930. Interestingly, we found that ADP presents high in vitro antibacterial activities against pathogenic bacteria from calves and sheep like baquiloprim31.

Antibacterial resistance is a serious problem which threatens human health in recent times, so it is very important for us to improve the rational use of drugs in order to prevent the development of resistance. However, we often overlook the antibacterial activity of the drug metabolites, which is a critical factor in formulating dosage regimen. Twelve metabolites of ADP can be detected in swine, broilers, carp and rats, and A1 and A2, which occupied 11.4% and 11.8% in swine, 12.8% and 14.0% in broilers, respectively, were the two main metabolites in these edible tissues25. In this study, the in vitro activities of A1 and A2 on Streptococcus from swine and Salmonella from chickens were equal to those of ADP. Therefore, we can have an inference that ADP would exhibit strong and long-lasting in vivo antibacterial activity when A1 and A2 are considered.

TMP, with a short half-life in domestic animals, presents shortcomings in maintaining sufficient plasma and tissue concentrations, so it is often used in combination with sulfonamides323334353637. In contrast to TMP, the superior pharmacokinetic properties of ADP allowed it as a single agent for therapeutic application. In this study, the in vivo antibacterial activity of ADP was determined by evaluating its efficacy in swine infected by S. suis type 2 CVCC607, which is a standard isolates and whose MIC is closed to the MIC50 of ADP to S. suis. As there were no recommended dose of ADP in veterinary clinic, administration dosage was set according to the pharmacodynamic and pharmacokinetic properties of ADP. It is generally accepted that in order to achieve a therapeutic effect, the plasma concentration of an antimicrobial should be higher or equal to the MIC for approximately half of the dosing time-interval of the drug38. Consequently, based on the MIC of ADP against S. suis CVCC607 and the pharmacokinetic values calculated after injection of ADP intramuscularly (Du Xi, unpublished data), 10 mg/kg b.w., 20 mg/kg b.w. and 40 mg/kg b.w. were set as the high, the medium and the low dosage groups, respectively, with once-daily administration.

Results of changes in rectal temperature, mental state, claudication and respiratory symptom indicated that all dosage groups of ADP exhibited therapeutic action to a certain extent, when compared with negative group. The efficacies of the high-dose treatment group and the middle-dose treatment group were better than that of the low-dose treatment group, while the efficacy of the middle-dose treatment group were equal to that of the positive control group. Therefore, the therapeutic dose of ADP recommended for swine streptococcosis is 20–40 mg/kg b.w., while 10 mg/kg b.w. can be used for prevention or consolidating its curative effect. Since 2, 4-diaminopyrimidines are often used as antibacterial synerists, there was no recommended dose for monotherapy in clinic. The combined dose of 40 mg/kg b.w. baquiloprim and sulphadimidine was the minimum recommended dosage for use as bolus in the field32. The oral suspension of TMP plus sulfadiazine administered at 24 mg/kg b.w. twice daily effectively treated the clinical signs of S. equi subsp zooepidemicus lower respiratory infection in horses33. In this study, the clinical efficacy of the single preparation of ADP is equivalent or better than those of the other 2, 4-diaminopyrimidine compound preparations.

In conclusion, this study has determined MICs and MBCs of ADP against common pathogens from swine, chickens, fishes, calves and sheep and established the antibacterial spectrum of ADP. It is shown that ADP has a good antibacterial activity which is identical with TMP, so do its main metabolites, A1 and A2. Phase II clinical study of ADP on therapeutic effect on swine streptococcosis has demonstrated that ADP is as active as compound sulfadiazine, which provides reasonable theoretical foundation for the clinical application of ADP. The overall in vitro and in vivo results provide predictive evidence that ADP has high antibacterial activity that can be used alone even though we are hunting appropriate medications for drug combinations.

Materials and Methods

Bacteria

E. coli ATCC25922, S. aureus ATCC29213, Enterococcus faecalis ATCC29212, Pseudomonas aeruginosa ATCC27853 and Streptococcus pneumonia ATCC49619 were obtained from America Type Culture Collection and were used as quality control strains. Standard strains such as E. coli CVCC220, CVCC1496, CVCC1500, CVCC 1502, CVCC 1513, CVCC1519 and CVCC2083, Salmonella typhimurium CVCC542 and CVCC541, Clostridium perfringens CVCC1125, CVCC1160 and CVCC2030, and Streptococcus suis CVCC607 and CVCC609 were purchased from Chinese Veterinary Culture Collection (Beijing, China). Isolated strains from swine, chickens, fishes, calves and sheep in livestock farms were also used in this study.

Animals and ethic statement

Sixty 3-week-old swine weighing 11 to 13 kg, which were completely healthy with no history of streptococcosis, were purchased from Jinlong Livestock and Poultry Co., Ltd (Wuhan, China). The animal houses were comfortable with standard temperature and humidity. They were free to access water and fed with a commercial diet free of antibiotics twice daily. All swine were allowed 7-day acclimation before the study. All the animal experiment procedures were performed in accordance with the guidelines and regulations of Animal Care Center, Hubei Science and Technology Agency in China (SYXK 2013-0044), and the experimental protocols were approved by the Ethics Committee of Huazhong Agricultural University, Wuhan, China.

Chemicals

ADP and its metabolites, A1 and A2, with chemical purity >99% were synthesized at National Reference Laboratory of Veterinary Drug Residues, Huazhong Agricultural University (Wuhan, China). TMP was purchased from China Institute of Veterinary Drugs Control (Beijing, China). Sulfadiazine Sodium Injection was bought from Zhengzhou Bairui Animal Pharmaceutical Co., LTD (Zhengzhou, China).

Antimicrobial susceptibility testing

Minimum inhibitory concentrations (MICs) of ADP and its main metabolites were determined by the broth microdilution technique according to the CLSI guidelines394041. Minimum bactericidal concentrations (MBCs) was determined as follows. After MIC reading, 10 μL bacteria suspension from wells in which the drug concentrations were higher than MIC were plated on agar and incubated overnight. MBC was the lowest concentration which could achieve 99.9% killing42. Using SPSS 19.0, the 50% minimum inhibitory concentration (MIC50), 90% minimum inhibitory concentration (MIC90), 50% minimum bactericidal concentration (MBC50) and 90% minimum bactericidal concentration (MBC90) were calculated.

The establishment of swine infectious model with Streptococcus

According to the results of in vitro antibacterial activity of ADP, S. suis CVCC607 was used for evaluating the therapeutic effect of ADP on swine streptococcicosis. The swine were randomly allocated into six groups (n = 10 for each group). Ten healthy swine were inoculated subcutaneously with 2 mL normal saline and were set as the blank group. Swine in the other five groups were inoculated subcutaneously with 2 mL inoculum containing 1010 CFU of S. suis CVCC607. The construction of model was successful when 70% of the swine gained the typical symptoms of streptococcicosis. To prevent cross-contamination, animals were housed in six different experimental rooms.

Treatment protocol

Treatment was applied upon streptococcicosis infection swine model. Swine in the negative-control group were monitored without drug treatment and swine in the positive-control group were treated with Compound Sulfadiazine Sodium (30 mg/kg b.w.). Swine in the low-dose treatment group, the middle-dose treatment group and the high-dose treatment group were treated with ADP injection at doses of 10 mg/kg b.w., 20 mg/kg b.w., and 40 mg/kg b.w., respectively. All the treatment groups were administered once daily for 5 days and observed for 15 days after the first administration.

Clinical observations

Health observations like mental states, appetite, rectal temperature and other clinical symptoms were recorded every day. The presences of lethargy, loss of appetite, claudication and respiratory abnormality (coughing or panting) were scored as follows in order to make a daily “clinical score”. Breath state: score 0, normal; score 1, increased breathing rate or occasional coughing; score 2, abdominal breathing or regular coughing; score 3, showing signs of severe dyspnea. Mental state: score 0, normal; score 1, mild depression; score 2, usually lying down or standing when gentle stimulated; score 3, holding up on forelegs in a sitting position or markedly depressed. Cure was defined when the rectal temperature was below 39.5 °C and both mental state score and breath state score were ≤1, while a medical improvement of the disease were considered effective4344.

Autopsy was carried out on the dead animals. Tissues were fixed with 10% formalin, dehydrated, immersed in the wax, cut into slices, and stained with hematoxylin eosin in order to observe the pathological changes of tissues. Swabs from the center of lesions were streaked on 5% sheep blood agar plates to make the bacteriological examination. Selected individual bacterial colony were examined using primers designed to amplify specific genes (5′-TTTGTCGGGAGGGTTACTTG-3′ and 5′-TTTGGAAGCGATTCATCTCC-3′ for CPS-2J gene; 5′-AAGTTCCTCGGTTTTGAGCA-3′ and 5′-GCAGCGTATTCTGTCAAACG-3′ for GDH gene) of S. suis serotype 2 and Streptococcus to make sure that the deaths were caused by S. suis serotype 2 infections. Mortality was recorded during the whole experiment and relative weight gain rate (RAW) was calculated through individual bodyweights at the beginning and finish of the study.

Statistical analysis

MIC50, MBC50, MIC90 and MBC90 were calculated by using SPSS software. Statistical analysis was performed with Student’s t-test and Bonferroni revision for comparing the clinical variables before and after treatment, and differences were considered to be statistically significant when the p-value was less than 0.05.

Additional Information

How to cite this article: Cheng, G. et al. The antibacterial activities of aditoprim and its efficacy in the treatment of swine streptococcosis. Sci. Rep. 7, 41370; doi: 10.1038/srep41370 (2017).

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.